MedTrace Logo

NOTAL-OCT V.2.5 vs Commercial OCT in AMD Patients

NCT03969303 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 287

Last updated 2020-11-12

No results posted yet for this study

Summary

Primary objective:

To evaluate the level of agreement between the NOTAL-OCT V2.5 and a commercial OCT in the presence of fluid as identified in the OCT images, in the central 10 degrees of the macula in AMD (Age-related Macular Degeneration) patients.

Secondary objectives:

1. To evaluate the level of agreement between the NOTAL-OCT V2.5 and a commercial OCT in the presence of fluid as identified in the OCT images, in the central 10 degrees of the macula in DME (Diabetic Macular Edema) patients.
2. To evaluate patient experience when self-operating the Notal-OCT V2.5.

Conditions

Interventions

DEVICE

Notal Vision Optical Coherence Tomography Device Version 2.5 (NOTAL-OCT V2.5)

OCT SCAN

Sponsors & Collaborators

  • Elman Retina Group

    collaborator OTHER

  • Notal Vision Ltd.

    lead INDUSTRY

Principal Investigators

  • Michael Elman · Michael Elman, M.D. 9114 Philadelphia Rd #310 Baltimore, Maryland 21237

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-10-20
Primary Completion
2019-07-11
Completion
2019-10-04

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03969303 on ClinicalTrials.gov